Can Chromosomal Abnormalities Go for IVF in China? PGT-A/SR Eligibility and Process Analysis

========== AI Summary ==========

========== Opening: Doctor's Decision Logic ==========

In reproductive genetics clinics, when a couple consults due to recurrent miscarriage, fetal abnormalities, or being a known carrier of a chromosomal structural abnormality, the doctor's starting point for decision-making is to clarify three questions: What is the specific type of abnormality? Is the carrier the male or female? Does the ovarian reserve and age allow completing a PGT cycle within a controllable time window? The answers to these three questions directly determine "whether IVF in China is possible" and "which PGT protocol to choose."

========================================================== Module A: Direct Answer ==========================================================

I. Direct Answer: Patients with Chromosomal Abnormalities Can Undergo IVF in China

Patients with chromosomal abnormalities can achieve fertility in China through Preimplantation Genetic Testing (PGT) technology, but the following basic conditions must be met:

• Definitive Genetic Diagnosis: Confirmation of the abnormality type via peripheral blood chromosome karyotyping, SNP array, or FISH.
• Choosing the Correct PGT Protocol: PGT‑A (aneuploidy screening) is suitable for numerical chromosomal abnormalities; PGT‑SR (structural rearrangement testing) is suitable for structural abnormalities such as balanced translocations, Robertsonian translocations, and inversions.
• Reproductive Center with PGT Qualification: There are currently over 80 medical institutions in China approved to perform third-generation IVF. Each center's technical platform (NGS, SNP array, FISH) and experience vary slightly.
• Ovarian Reserve Sufficient for One or More Ovarian Stimulation Cycles: A PGT cycle requires obtaining a sufficient number of eggs (usually recommended ≥ 8 mature oocytes) to form blastocysts suitable for biopsy.

========================================================== Module B: Why This Problem Occurs ==========================================================

II. Why Chromosomal Abnormalities Lead to Fertility Difficulties

During the formation of gametes (sperm or eggs), carriers of chromosomal structural abnormalities undergo abnormal chromosome segregation and recombination, producing a large number of unbalanced gametes. Taking balanced translocation as an example, carriers form a quadrivalent during meiosis. Theoretically, only 1/9 of gametes have a completely normal chromosome composition, another 1/9 are balanced translocation carriers, and the remaining 7/9 are unbalanced gametes. Most embryos formed after fertilization with unbalanced gametes arrest early or miscarry; a few may survive but with congenital defects.

The theoretical proportion of normal gametes for Robertsonian translocation is slightly higher (about 1/6), but it also faces a high proportion of unbalanced embryos. The recombination frequency for chromosomal inversions (especially pericentric inversions) is related to the length of the inverted segment; the longer the segment, the higher the proportion of unbalanced gametes.

This is why carriers of chromosomal abnormalities have a significantly higher probability of recurrent miscarriage, embryonic arrest, or abnormal offspring after natural conception compared to the general population.

========================================================== Module C: Doctor's Perspective ==========================================================

III. How Doctors Evaluate and Decide

When deciding whether to recommend PGT, reproductive doctors systematically assess the following dimensions:

• Type of Abnormality and Carrier Sex: Male carriers of balanced translocations typically produce a higher proportion of normal sperm than female carriers produce normal eggs, related to sex differences in meiosis.
• Age and Ovarian Reserve: After age 35, the rate of oocyte aneuploidy rises rapidly. Combined with the proportion of unbalanced embryos from structural abnormalities, the transferable embryo rate can significantly decrease. AMH, antral follicle count (AFC), and basal FSH are commonly used assessment indicators.
• Previous Reproductive History: Patients with a history of normal childbirth or a successful PGT cycle have a relatively higher probability of obtaining transferable embryos again.
• Genetic Counseling Results: It is necessary to rule out de novo mutations, mosaicism, and whether other family members carry the same abnormality.

Doctors also assess whether patients are suitable for adjunctive techniques such as in vitro maturation of immature oocytes or oocyte activation, but these techniques are still in the clinical research stage in China and are not routine options.

========================================================== Module D: Differences Across Age Groups ==========================================================

IV. Differences Across Age Groups

Age is one of the core variables affecting PGT outcomes. The following table shows key differences for carriers of chromosomal abnormalities undergoing PGT across different age ranges:

Age Range	Average Number of Eggs Retrieved	Blastocyst Formation Rate	Estimated Proportion of Transferable Embryos	Key Clinical Considerations
< 30 years	12–18	45%–55%	15%–25%	Good ovarian response, higher probability of transferable embryos; consider prioritizing embryo accumulation.
30–34 years	10–15	40%–50%	10%–20%	Age-related aneuploidy begins to rise; consider concurrent PGT‑A screening.
35–39 years	7–12	35%–45%	5%–15%	Oocyte quality declines; may require multiple stimulation cycles to accumulate embryos.
≥ 40 years	4–8	25%–35%	3%–8%	Probability of transferable embryos significantly reduced; thorough communication of expectations needed.

The above data comes from clinical statistics of multiple reproductive centers in China from 2018‑2023. Individual variation is large, and this is for reference only. Doctors will make individualized predictions based on the patient's specific situation.

========================================================== Module E: Differences Across Hospitals ==========================================================

V. Differences Across Hospitals

In China, reproductive centers authorized to perform PGT differ in technical platforms, laboratory experience, and genetic counseling capabilities, mainly reflected in three aspects:

• Testing Technology Platform: Most centers use next-generation sequencing (NGS) for PGT‑A and PGT‑SR; a few still use SNP arrays or FISH. NGS offers advantages in resolution, throughput, and cost but requires higher laboratory standards.
• Embryo Biopsy Timing and Method: The current mainstream is trophectoderm biopsy at the blastocyst stage (day 5–6), which is less disruptive to the embryo than cleavage-stage biopsy. Some centers have extensive experience in biopsy and vitrification, ensuring post-biopsy blastocyst survival rates ≥ 95%.
• Genetic Counseling and Family Verification Capability: Handling complex structural abnormalities (e.g., complex translocations, inversions combined with other variants) requires experienced geneticists to participate in protocol design. The level of genetic counseling at different centers directly affects the accuracy and success rate of the testing protocol.

When choosing a hospital, patients should focus on the center's number of cases and technical details for handling similar chromosomal abnormalities, rather than just looking at overall success rates.

========================================================== Module G: Most Easily Overlooked Details ==========================================================

VI. Most Easily Overlooked Details

In clinical counseling, the following details are often overlooked by patients and even some doctors, but they have a substantial impact on treatment outcomes:

• Impact of Mosaicism: Some chromosomal abnormalities exist in mosaic form (e.g., low-level mosaic Turner or mosaic translocation), which may be missed by peripheral blood karyotyping. Additional FISH or SNP array verification is recommended.
• De Novo Mutations and Family Verification: About 10%–15% of structural abnormalities are de novo mutations, with normal parental karyotypes. In such cases, probe design for the PGT protocol must be based on the patient's own breakpoint information.
• Abnormalities Undetectable by PGT: PGT technology may miss microdeletions/microduplications < 5 Mb, low-level mosaicism, uniparental disomy (UPD), etc. For known pathogenic CNVs, custom probes need to be designed.
• Necessity of Prenatal Diagnosis: PGT is a screening technology, not a diagnostic technology. Invasive prenatal diagnosis (amniocentesis + chromosome karyotyping / SNP array) is recommended for all PGT pregnancies to confirm the fetal chromosomal status.

========================================================== Module I: Actual Process ==========================================================

VII. Actual Process

The standard process for PGT treatment in China for patients with chromosomal abnormalities includes the following stages, with a total duration typically of 3‑6 months:

1. Preliminary Preparation (1–2 months)

• Genetic Counseling and Diagnosis: Peripheral blood chromosome karyotyping for both partners, and SNP array or FISH verification if necessary.
• Family Verification: Karyotyping of parents or children is recommended to distinguish hereditary vs. de novo mutations, aiding probe design.
• Fertility Assessment: Female: AMH, AFC, basal sex hormones; Male: semen analysis + sperm morphology + sperm DNA fragmentation index.
• Infectious Disease Screening: Hepatitis B, Hepatitis C, Syphilis, HIV, TORCH, etc.
• Document Preparation: Marriage certificate, ID card, birth permit (according to local policies).

2. Ovarian Stimulation and Egg Retrieval (2–3 weeks)

• Individualized stimulation protocol chosen based on female age, AMH, AFC (antagonist protocol, short protocol, luteal phase protocol, etc.).
• Ultrasound monitoring of follicle development, timely trigger, transvaginal egg retrieval.
• ICSI fertilization performed 2–3 hours after retrieval (to avoid paternal chromosome contamination from conventional IVF).

3. Embryo Culture and Biopsy (5–7 days)

• Embryo quality assessed on day 3 post-fertilization, culture continued to day 5–6 for blastocyst formation.
• Trophectoderm biopsy (about 3–5 cells) performed on blastocysts meeting biopsy criteria (usually requiring inner cell mass and trophectoderm rating ≥ BC).
• Biopsied blastocysts are immediately vitrified and cryopreserved.

4. PGT Testing (2–4 weeks)

• Biopsied cells undergo whole genome amplification (WGA) followed by NGS or SNP array testing.
• Data analysis: determining chromosome copy number variations, structural rearrangement breakpoints, loss of heterozygosity, etc.
• Testing report issued, distinguishing "chromosomally normal embryos," "balanced carrier embryos," and "unbalanced embryos."

5. Frozen Embryo Transfer (1–2 months)

• Based on test results, select 1 chromosomally normal or balanced carrier blastocyst for transfer.
• Endometrial preparation required before transfer (natural cycle or hormone replacement cycle). Transfer when endometrial thickness ≥ 7 mm and morphology is good.
• Blood test for β‑hCG on day 9–11 post-transfer to confirm pregnancy.

6. Post-Pregnancy Prenatal Diagnosis (18–22 weeks gestation)

• After clinical pregnancy, amniocentesis is performed at 18–22 weeks gestation for fetal chromosome karyotyping + SNP array.
• Confirm fetal chromosomal status and cross-validate with PGT results.

========================================================== Module N: Special Situation Management ==========================================================

VIII. Special Situation Management

Different types of chromosomal abnormalities have differences in PGT protocol design. The following are management principles for common special situations:

8.1 Balanced Translocation

Balanced translocation is one of the most common types of chromosomal structural abnormalities. PGT‑SR first requires determining the translocation breakpoints through breakpoint analysis, then designing probes covering the breakpoint regions or using SNP arrays for linkage analysis. For male carriers, some centers recommend sperm FISH analysis to assess the proportion of normal sperm, helping predict PGT outcomes.

8.2 Robertsonian Translocation

Robertsonian translocation involves the fusion of two acrocentric chromosomes (13, 14, 15, 21, 22). The theoretical probability of carriers producing normal embryos is about 1/6, but due to differences in segregation behavior of different chromosome pairs, the actual probability ranges from 8%–25%. PGT‑SR protocols typically use SNP arrays combined with family linkage analysis, which can distinguish between normal embryos and balanced carrier embryos.

8.3 Chromosomal Inversion

The reproductive risk for carriers of pericentric inversions depends on the length of the inverted segment. The longer the segment, the higher the proportion of unbalanced gametes formed by recombination during meiosis. For carriers with an inverted segment ≥ 30% of the total chromosome length, the benefit of PGT‑SR is clear; for those with shorter inverted segments, natural pregnancy outcomes may be better, but PGT is still recommended to reduce miscarriage risk.

8.4 Microdeletion/Microduplication

For known pathogenic microdeletions (e.g., 22q11.2 deletion, 15q11.2 deletion, etc.), PGT requires custom targeted probes or high-resolution SNP arrays. Due to the small size of microdeletions, the resolution of conventional PGT‑A is insufficient for reliable detection; a targeted testing protocol must be used.

========================================================== Closing: Doctor's Recommendation ==========================================================

---

Doctor's Recommendation: Before undergoing PGT treatment in China, patients with chromosomal abnormalities should first complete systematic genetic counseling and fertility assessment to clarify the type of abnormality, the probability of obtaining transferable embryos, and the potential number of cycles needed. For women with low ovarian reserve or age ≥ 38, consider an embryo accumulation strategy (i.e., unified testing after multiple stimulation cycles) to increase the chance of obtaining normal embryos. Maintain reasonable expectations during treatment and understand that PGT is a screening, not diagnostic, technology. Prenatal diagnosis is an essential step for final confirmation of the fetal chromosomal status.

===== End Identifier =====